Active, not recruitingPhase 3NCT04431726

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

Studying Hemophilia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hoffmann-La Roche
Principal Investigator: Clinical Trials
Hoffmann-La Roche
Intervention: Emicizumab(drug)
Enrollment: 55 enrolled
Eligibility: All sexes
Timeline: 2021 – 2030

Study locations (30)

Phoenix Children's Hospital, Phoenix, Arizona, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States
Tulane University Health Sciences Center, New Orleans, Louisiana, United States
University of Michigan, Ann Arbor, Michigan, United States
Seattle Children's Hospital, Seattle, Washington, United States
The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Royal Children's Hospital, Parkville, Victoria, Australia
Perth Children's Hospital, Nedlands, Western Australia, Australia
Medizinische Universität Wien, Vienna, Austria
Cliniques Universitaires St-Luc, Brussels, Belgium
UZ Leuven Gasthuisberg, Leuven, Belgium
Hospital das Clínicas Faculdades Médicas de Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
The Hospital for Sick Children, Toronto, Ontario, Canada
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04431726 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia →

← Back to all trials